News Cyberattack on Boston Scientific causes global ops disruptio... Medical technology company Boston Scientific became the target of a cyberattack this week.
News US MCT8 deficiency patients get 1st drug as Emcitate debuts Egetis has launched the first-ever therapy for the ultra-rare disease MCT8 deficiency in the US, with a list price of $950,000 per year.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
